A handful of big names in drug discovery and development are among the 500 “most responsible,” according to Newsweek. The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of the largest public corporations around. Companies were judged with an overall…
What makes something ‘undruggable’?
A growing number of researchers believe the pharma industry has entered a new wave of innovation involving multispecific medicines. Among them is Ray Deshaies, a biochemist and cell biologist, who is the SVP of global research at Amgen. In 2020, Deshaies wrote an article for Nature explaining why multispecific drugs may grant access to portions of the…
Amgen finalizes Teneobio acquisition
Amgen (NSDQ:AMGN) has acquired privately-held immunotherapy specialist Teneobio (Newark, California). The transaction includes an upfront $900 million upfront payment and future contingent milestone payments worth up to an additional $1.6 billion. Tenebio’s stated mission was to tap human heavy-chain antibodies to “redirect the immune system to safely fight disease.” Earlier this year, it had three drug…
Biosimilars adoption growing, but the market remains nascent
While biosimilar adoption remains at an early stage in the U.S., biosimilar adoption is ticking up. Biosimilar penetration for Roche’s Avastin (bevacizumab) is especially high at 69%. In addition, biosimilars for Genentech’s Herceptin and Amgen’s Neupogen have also achieved a market penetration of 57% and 62%, respectively, according to IQVIA data based on late June sales data.…
After flunking one study, Amgen’s tezepelumab shows promise for asthma
Amgen and AstraZeneca have announced that the experimental monoclonal antibody tezepelumab demonstrated a clinically meaningful reduction in annualized asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients. In the NAVIGATOR Phase 3 trial, the drug led to a 56% reduction in AAER versus placebo over 52 weeks when used as part of the standard of…
Amgen Q3 revenues up 12% — but growth questions remain
Amgen (NSDQ:AMGN) announced third-quarter earnings per share of $4.37, beating the consensus forecast of $3.80. Biosimilars growth and a strong base business drove growth in the quarter ending on Sept. 30. The company has been relatively steady in 2020, growing 11% in the first quarter and 6% in the second. “Our performance in the third quarter…